Courtesy of Omni La Costa Resort & Spa

6th International Conference on Accelerating Biopharmaceutical Development (AccBio 2019)

February 17-20, 2019
Add to Calendar

This conference series is dedicated to strategies, technologies and capabilities that accelerate biopharmaceutical development.

Abstract Submissions are open until January 17, 2019.

Submit an Abstract Registration Info

AIChE’s thoughts are with those affected by the California wildfires and the first responders doing all they can to help.​

Sessions:

  • New Modalities
  • Advancements in Data Technologies
  • Manufacturing Technologies
  • Patient Centric Process Development

Keynote Speakers:

Invited Speakers:

Conference Co-Chairs:

  • Stefanie Pluschkell, Pfizer
  • Aine Hanly, AMGEN

Steering Committee:

  • Dana Anderson, Denali Therapeutics
  • Hanne Bak, Regeneron
  • Tim Charlebois, Pfizer
  • Jon Coffman, Boehringer-Ingelheim
  • Charles Cooney, Massachusetts Institute of Technology
  • Rohini Deshpande, AMGEN
  • Brendan Hughes, Bristol-Myers Squibb
  • Brian Kelley, VIR Biotechnology, Inc.
  • Kelvin Lee, University of Delaware
  • Christopher Love, Massachusetts Institute of Technology
  • Gregg Nyberg, Merck
  • Dean Pettit, Just Biotherapeutics
  • Arup Roy, Lilly
  • Jeffrey Salm, Pfizer
  • Eugene Schaefer, Janssen
  • Nigel Titchener-Hooker, University College London
  • Ganesh Vedantham, AMGEN
  • Nick Warne, Pfizer

Featured Speakers

Regina Barzilay

Regina Barzilay is a Delta Electronics professor in the Department of Electrical Engineering and Computer Science and a member of the Computer Science and Artificial Intelligence Laboratory at the Massachusetts Institute of Technology. Her research interests are in natural language processing, applications of deep learning to chemistry and oncology. She is a recipient of various awards including the NSF Career Award, the MIT Technology Review TR-35 Award, Microsoft Faculty Fellowship and several Best Paper Awards at NAACL and ACL. In 2017, she received a MacArthur fellowship, an ACL...Read more

Matthew James Clemente

Matthew James Clemente currently serves as the Senior Director of Delivery Systems Engineering & Technology at Eli Lilly & Company. He is responsible for the leadership of the research and development organization responsible for the engineering and design of Eli Lilly’s delivery, device and connected solutions portfolio. Previously as the Director and Chief Technology Officer, he developed an emerging portfolio of electromechanical delivery devices, applications and algorithms that serve a variety of therapeutic areas and formulations. He has served this organization since October...Read more

Tushar Jain

Tushar Jain is a Principal Scientist at Adimab. For the past 9 years at Adimab, Tushar has worked on developing machine learning and statistical models to predict developability characteristics of antibodies to ultimately design antibody libraries with favorable downstream and PK characteristics. In addition, Tushar has a keen interest in interpreting insights obtained from such approaches using structural models to better drive our understanding of antibody behavior.

Tushar Jain holds a PhD in Chemical Engineering from the University of Wisconsin - Madison

 ...Read more

Shailen Singh

Shailen Singh is a director at Merck and leads the upstream commercialization activities within biologics process development & commercialization group in Manufacturing Division. He has over 10 years of experience in upstream process development, commercialization and manufacturing science & technology activities. Before Merck he was at Medimmune leading similar activities.  Shailen has a PhD from University of California Riverside and masters/bachelors from IIT Delhi in Biochemical Engineering....Read more

Cenk Undey

Dr. Undey joined Amgen in 2003 and has held positions of increasing responsibility in Process Development which included providing manufacturing support, continuous process improvement of commercial products, and technology transfers. He has formed the Digital Integration and Predictive Technologies in 2013, a corporate group with a mission to transform Amgen business from data rich to decision smart. His group’s aim is to improve process and product understanding, process optimization, reduce process development cycle time hence increasing speed to market with reduced development costs...Read more

Michael W. Vandiver

Michael (Mike) Vandiver is Vice President, Manufacturing & Plant Design at Just Biotherapeutics. Mike has over 30 years of biopharmaceutical process development and manufacturing experience that includes direct involvement in the development and transfer of commercial processes for Enbrel®, Vectibix®, and Prolia®/XGEVA®. At Just Biotherapeutics, he has led the effort to bring J.Plant and J.Pod™ clinical and commercial biomanufacturing facilities online. These rapid, low-cost, facility designs leverage continuous manufacturing technologies to significantly reduce the cost of goods...Read more